Olmesartán/Amlodipino Tecnigen (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine, the active ingredients in Olmesartán/Amlodipino Tecnigen, are antihypertensive agents presented as oral tablets for oral use. They treat high blood pressure in adult patients, providing combined blockade of the renin‑angiotensin system and calcium‑channel mediated vasodilation. The combination is indicated for patients who require dual therapy to achieve target blood pressure levels and may improve adherence compared with separate tablets.

GNH USA supplies Olmesartán/Amlodipino Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable logistics.

Olmesartán/Amlodipino Tecnigen is used in the management of hypertension, acting on the renin‑angiotensin system and vascular smooth muscle tone. - Essential hypertension: lowers systolic and diastolic blood pressure to help patients reach guideline‑recommended targets. - Hypertension with cardiovascular risk: provides combined ARB and calcium‑channel blockade for enhanced blood pressure control. - Uncontrolled hypertension on monotherapy: adds additive antihypertensive effect when a single agent is insufficient. - Isolated systolic hypertension: reduces elevated systolic pressure in elderly patients. - Hypertension in patients with diabetes: offers renal protective benefits alongside blood pressure reduction.

Adverse reactions reported with the Olmesartan/Amlodipine combination include both common and less frequent events. Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pressure in the head. - Peripheral edema: swelling of ankles or lower legs. - Flushing: transient warmth and redness of the skin. - Fatigue: feeling of tiredness or lack of energy. - Palpitations: awareness of heartbeat irregularities. Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatic enzyme elevation: increased ALT/AST indicating liver stress. - Myocardial infarction: acute heart attack symptoms. - Arrhythmias: abnormal heart rhythms that may require medical attention. - Acute kidney injury: sudden decline in renal function.

When prescribing Olmesartan/Amlodipine, clinicians should consider several precautionary measures to ensure patient safety. - Renal function monitoring: assess serum creatinine and eGFR before and during therapy. - Electrolyte balance: check potassium levels, especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease; monitor liver enzymes. - Pregnancy: contraindicated; avoid use in women who are pregnant or may become pregnant. - Elderly patients: start at lower dose and monitor for hypotension and dizziness. - Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipine may interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - ACE inhibitors or other ARBs: combined use can increase risk of hyperkalemia and renal dysfunction. - Aliskiren in diabetic patients: may cause renal impairment and hyperkalemia. - Potassium‑sparing diuretics: additive effect on serum potassium leading to hyperkalemia. - NSAIDs: can reduce antihypertensive effect and impair renal function. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., diltiazem, ketoconazole): may raise amlodipine concentrations, increasing risk of edema and hypotension. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower amlodipine levels, reducing efficacy. - Diuretics: concurrent use may enhance blood pressure lowering, requiring dose adjustment. - Lithium: ARBs can increase lithium levels, risking toxicity. - Other antihypertensives: additive blood pressure reduction may cause symptomatic hypotension.